tradingkey.logo

Ocugen Announces Positive Preliminary Phase 2 Data From Ocu410 Modifier Gene Therapy For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

ReutersJan 15, 2026 1:17 PM

- Ocugen Inc OCGN.O:

  • OCUGEN ANNOUNCES POSITIVE PRELIMINARY PHASE 2 DATA FROM OCU410 MODIFIER GENE THERAPY FOR GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION

  • OCUGEN INC - NO SERIOUS ADVERSE EVENTS REPORTED IN PHASE 1 AND 2 TRIALS

  • OCUGEN INC - PHASE 2 SHOWS 46% LESION GROWTH REDUCTION VERSUS CONTROL

  • OCUGEN INC: REPORTING FULL DATA FROM OCU410 PHASE 2 CLINICAL TRIAL LATER THIS QUARTER AND INITIATING PHASE 3 IN 2026

  • OCUGEN INC: COMPANY REMAINS ON TRACK FOR A BIOLOGICS LICENSE APPLICATION (BLA) FILING FOR OCU410 IN 2028

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI